Option Care Health (NASDAQ:OPCH – Get Free Report) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.420-0.450 for the period, compared to the consensus estimate of 0.330. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. […]

Zumiez (NASDAQ:ZUMZ – Get Free Report) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.72-0.77 for the period, compared to the consensus estimate of $0.88. The company issued revenue guidance of $275-277 million, compared to the consensus revenue estimate of $285.49 million. […]

Ichor (NASDAQ:ICHR – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of -0.210 for the period, compared to the consensus earnings per share estimate of 0.270. The company issued revenue guidance of $233.0 million-$233.0 million, compared to the consensus revenue […]

AtriCure (NASDAQ:ATRC – Get Free Report) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share guidance of -0.800–0.740 for the period, compared to the consensus earnings per share estimate of -0.740. The company issued revenue guidance of $465.3 million-$465.3 million, compared to the consensus revenue estimate of $460.9 million. AtriCure […]

NeoGenomics (NASDAQ:NEO – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.080-0.100 for the period, compared to the consensus estimate of 0.100. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $662.0 million. […]

Walgreens Boots Alliance (NASDAQ:WBA – Get Free Report) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $1.40-$1.80 for the period, compared to the consensus estimate of $1.52. Walgreens Boots Alliance also updated its FY 2025 guidance to 1.400-1.800 EPS. Walgreens Boots Alliance Trading […]

WD-40 (NASDAQ:WDFC – Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 5.200-5.450 for the period, compared to the consensus EPS estimate of 5.360. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $623.0 million. WD-40 also updated its FY25 […]

WD-40 (NASDAQ:WDFC – Get Free Report) updated its FY25 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $5.20-$5.45 for the period, compared to the consensus estimate of $5.36. Analyst Upgrades and Downgrades A number of brokerages have issued reports on WDFC. DA Davidson reiterated a “buy” rating and issued a […]

NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share guidance of 0.080-0.100 for the period, compared to the consensus earnings per share estimate of 0.100. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $662.0 million. NeoGenomics […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated […]

Walgreens Boots Alliance (NASDAQ:WBA – Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.400-1.800 for the period, compared to the consensus earnings per share estimate of 1.520. The company issued revenue guidance of -. Wall Street Analysts Forecast Growth A […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.950-5.350 for the period, compared to the consensus estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics […]

Helen of Troy (NASDAQ:HELE – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 7.150-7.400 for the period, compared to the consensus EPS estimate of 7.210. The company issued revenue guidance of $1.9 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.000-4.200 for the period, compared to the consensus earnings per share estimate of 4.140. The company issued revenue guidance of $970.0 million-$1.0 billion, compared to the consensus revenue […]

Helen of Troy (NASDAQ:HELE – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 7.150-7.400 for the period, compared to the consensus estimate of 7.210. The company issued revenue guidance of $1.9 billion-$1.9 billion, compared to the consensus revenue estimate […]

AngioDynamics (NASDAQ:ANGO – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of ($0.38)-($0.34) for the period, compared to the consensus estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY […]

Penguin Solutions (NASDAQ:PENG – Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.30-$1.70 for the period, compared to the consensus EPS estimate of $1.65. The company issued revenue guidance of $1.29-$1.40 billion, compared to the consensus revenue estimate of $1.34 billion. Penguin Solutions […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.950-5.350 for the period, compared to the consensus earnings per share estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $4.00-$4.20 for the period, compared to the consensus earnings per share estimate of $4.14. The company issued revenue guidance of $970-$1.02 billion, compared to the consensus revenue estimate of $1.00 billion. Halozyme Therapeutics […]

AngioDynamics (NASDAQ:ANGO – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.380–0.340 for the period, compared to the consensus estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 […]

Simulations Plus (NASDAQ:SLP – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.070-1.200 for the period, compared to the consensus earnings per share estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. […]

Apogee Enterprises (NASDAQ:APOG – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 4.900-4.900 for the period, compared to the consensus estimate of 5.080. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of […]

Tenable (NASDAQ:TENB – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus earnings per share estimate of 0.340. The company issued revenue guidance of $229.0 million-$233.0 million, compared to the consensus revenue […]

Applied Materials (NASDAQ:AMAT – Get Free Report) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share guidance of 2.110-2.470 for the period, compared to the consensus earnings per share estimate of 2.300. The company issued revenue guidance of $6.8 billion-$7.6 billion, compared to the consensus revenue estimate of $7.2 […]